Development of an Innovative Intradermal siRNA Delivery System Using a Combination of a Functional Stearylated Cytoplasm-Responsive Peptide and a Tight Junction-Opening Peptide.
As a new category of therapeutics for skin diseases including atopic dermatitis (AD), nucleic acids are gaining importance in the clinical setting. Intradermal administration is noninvasive and improves patients' quality of life. However, intradermal small interfering RNA (siRNA) delivery is difficult because of two barriers encountered in the skin: intercellular lipids in the stratum corneum and tight junctions in the stratum granulosum. Tight junctions are the major barrier in AD; therefore, we focused on functional peptides to devise an intradermal siRNA delivery system for topical skin application. In this study, we examined intradermal siRNA permeability in the tape-stripped (20 times) back skin of mice or AD-like skin of auricles treated with 6-carboxyfluorescein-aminohexyl phosphoramidite (FAM)-labeled siRNA, the tight junction modulator AT1002, and the functional cytoplasm-responsive stearylated peptide STR-CH₂R₄H₂C by using confocal laser microscopy. We found that strong fluorescence was observed deep and wide in the epidermis and dermis of back skin and AD-like ears after siRNA with STR-CH₂R₄H₂C and AT1002 treatment. After 10 h from administration, brightness of FAM-siRNA was significantly higher for STR-CH₂R₄H₂C + AT1002, compared to other groups. In addition, we confirmed the nontoxicity of STR-CH₂R₄H₂C as a siRNA carrier using PAM212 cells. Thus, our results demonstrate the applicability of the combination of STR-CH₂R₄H₂C and AT1002 for effective intradermal siRNA delivery.
Laboratory of Pharmaceutics and Drug Delivery, Department of Pharmaceutical Science, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan. ibaraki@toyaku.ac.jp.
Hisako
H
Ibaraki
Laboratory of Pharmaceutics and Drug Delivery, Department of Pharmaceutical Science, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan. kanazawa@toyaku.ac.jp.
Takanori
T
Kanazawa
Laboratory of Pharmaceutics and Drug Delivery, Department of Pharmaceutical Science, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan. takasima@toyaku.ac.jp.
Yuuki
Y
Takashima
Laboratory of Pharmaceutics and Drug Delivery, Department of Pharmaceutical Science, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan. okada@toyaku.ac.jp.
Hiroaki
H
Okada
Laboratory of Pharmaceutics and Drug Delivery, Department of Pharmaceutical Science, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan. setayas@toyaku.ac.jp.
Yasuo
Y
Seta
D000287:Administration, Topical; D000327:Adsorption; D000818:Animals; D003593:Cytoplasm / Q000378:metabolism; D003876:Dermatitis, Atopic; D016503:Drug Delivery Systems; D018014:Gene Transfer Techniques; D015603:Keratinocytes / Q000378:metabolism; D008297:Male; D051379:Mice; D010455:Peptides / Q000008:administration & dosage* / Q000737:chemistry; D010539:Permeability; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000737:chemistry; D012867:Skin / Q000378:metabolism*; D019108:Tight Junctions / Q000378:metabolism*
D010455:Peptides; D034741:RNA, Small Interfering
atopic dermatitis; drug delivery; peptide; siRNA; transdermal
J Allergy Clin Immunol. 2000 May;105(5):860-76
10808164
Exp Dermatol. 2000 Jun;9(3):165-9
10839713
Nat Med. 2000 Nov;6(11):1253-7
11062537
Bioconjug Chem. 2001 Nov-Dec;12(6):1005-11
11716693
Biotechniques. 2002 Jul;33(1):190-2, 194
12139245
Int J Pharm. 2008 Mar 3;351(1-2):8-14
17954018
Exp Dermatol. 2007 Dec;16(12):999-1006
18031459
Eur J Pharm Biopharm. 2008 May;69(1):231-7
18039562
Bioorg Med Chem Lett. 2008 Aug 15;18(16):4584-6
18667315
Curr Protoc Nucleic Acid Chem. 2009 Mar;Chapter 16:Unit 16.1
19319858
Int J Pharm. 2010 Jan 4;383(1-2):157-60
19732811
G Ital Dermatol Venereol. 2009 Dec;144(6):689-700
19907407
Immunol Cell Biol. 2010 May-Jun;88(4):400-9
20351749
Int J Pharm. 2010 Oct 15;398(1-2):219-24
20674725
Chem Pharm Bull (Tokyo). 2011;59(2):196-201
21297299
J Pharmacol Exp Ther. 2011 Aug;338(2):443-50
21531792
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15816-21
21903933
Carbohydr Polym. 2013 Apr 15;94(1):634-41
23544584
Biomaterials. 2014 Mar;35(10):3435-42
24424208
J Control Release. 2014 Nov 28;194:148-56
25192942
Drug Des Devel Ther. 2015 Mar 27;9:1815-23
25848218
Biomaterials. 2015 Oct;66:41-52
26196532
Lancet. 2016 Mar 12;387(10023):1109-1122
26377142
J Clin Immunol. 2015 Oct;35(7):681-8
26453584
Biol Pharm Bull. 2016;39(7):1206-10
27374295
Biomed Microdevices. 2016 Aug;18(4):67
27422107
Drug Deliv Transl Res. 2017 Feb;7(1):16-26
27562294